Lower hepatocellular carcinoma surveillance in metabolic dysfunction‐associated steatotic liver disease: Impact on treatment eligibility

Documenti analoghi

• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
  di: Toshifumi Tada, et al.
  Pubblicazione: (2025)
• Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Akihito Shiomi, et al.
  Pubblicazione: (2024)
• Treatment of liver cirrhosis in the era of steatotic liver disease
  di: Masahito Shimizu
  Pubblicazione: (2024)
• Metabolic dysfunction‐associated steatotic liver disease is a risk factor for gallstones: A multicenter cohort study
  di: Tomonori Cho, et al.
  Pubblicazione: (2025)